Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab Effects on Nasal Adaptive Immune Memory in CRSwNP
NCT06107101Phase 4Not yet recruiting
- Sponsor
- St. Paul's Sinus Centre
- Start
- Jun 2024
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of mepolizumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by St. Paul's Sinus Centre. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
mepolizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT06107101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06107101.